News Sentiment

AGMB sentiment intelligence

AgomAb Therapeutics NV American Depositary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.04 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-8.0% over one week, +9.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Enterprise value to EBIT forward of AgomAb Therapeutics NV – NASDAQ:AGMB

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -8.0% Price reacting lower
Trend fit Trend inactive 9.7% over four weeks
Fair value -1.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 29
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 9
TradingView 6
Finviz 3
MT Newswires 2
Investing.com Nigeria 2
Seeking Alpha 2
The Manila Times 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 17
Analyst action 3
Regulatory and legal 3
Deals and strategy 3
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
TradingView Direct company coverage

Enterprise value to EBIT forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article provides access to the "Enterprise value to EBIT forward" metric for AgomAb Therapeutics NV (NASDAQ:AGMB) on TradingView. It indicates that the market is currently closed with no trades recorded. The content is primarily a gateway to financial data and tools offered

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 10:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This page provides financial data specifically regarding the "Price to book forward" for AgomAb Therapeutics NV (NASDAQ: AGMB). The article states that the market is currently closed with no trades recorded. It indicates that the data is provided by ICE Data Services and FactSet,

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:40
Source
TradingView
Finviz Direct company coverage

AGMB - AgomAb Therapeutics NV ADR Short Interest

This article provides a detailed overview of AgomAb Therapeutics NV ADR (AGMB) stock performance and financial data. It includes key metrics such as market capitalization, enterprise value, various financial ratios, and short interest details, alongside recent stock performance a

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Finviz
Finviz Direct company coverage

AGMB - AgomAb Therapeutics NV ADR Latest SEC Filings

This article provides the latest SEC filing information for AgomAb Therapeutics NV ADR (AGMB). It includes a comprehensive overview of financial data, key metrics, stock performance, and insider/institutional ownership details for the company as of July 10.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 23:39
Source
Finviz
TradingView Direct company coverage

AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB)

This article provides access to the financial actuals and estimates for AgomAb Therapeutics NV (NASDAQ:AGMB) on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and metrics. The platform enables comparison o

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 23:10
Source
TradingView
TradingView Direct company coverage

AGMB Forecast — Price Target — Prediction for 2027

This article provides a price target for AgomAb Therapeutics NV (AGMB) for 2027, based on analysis from 5 analysts. It indicates a price target of 32.21, with no specific max or min estimates given by the analysts. The content emphasizes that this information is not investment ad

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 18:10
Source
TradingView
Taiwan News Direct company coverage

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab Therapeutics has announced the design of its Phase 2b NOV-ERA study for ontunisertib, an investigational oral therapy for Fibrostenosing Crohn’s Disease (FSCD). The company has aligned with the FDA on key study elements, including a novel primary endpoint of endoscopic pas

Tone
Positive 72/100
Event
Regulatory and legal
Published
24 Jun 2026 17:10
Source
Taiwan News
Investing.com Nigeria Direct company coverage

Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com

Agomab Therapeutics Nv has filed a Form 6K for June 23. This filing is a routine report indicating corporate actions or financial updates from the company. The stock symbol for Agomab Therapeutics Nv is AGMB.

Tone
Positive 58/100
Event
Market update
Published
24 Jun 2026 05:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Agomab’s Crohn’s study targets an endoscopic pass-through test

Agomab (Nasdaq: AGMB) has announced the design for its NOV-ERA Phase 2b study of ontunisertib, an oral ALK5 inhibitor, for fibrostenosing Crohn's disease (FSCD). The study, which has aligned with the FDA on its design and primary endpoint of endoscopic passability at Week 24, wil

Tone
Positive 71/100
Event
Market update
Published
23 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Agomab (AGMB) sets FDA-aligned Phase 2b trial for fibrostenosing Crohn’s

Agomab Therapeutics (AGMB) has detailed the design of its FDA-aligned Phase 2b NOV-ERA trial for ontunisertib, targeting fibrostenosing Crohn’s disease (FSCD), a condition affecting 46% of Crohn's patients with no approved drug treatments. The study, set to enroll up to 320 adult

Tone
Positive 63/100
Event
Market update
Published
23 Jun 2026 20:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

H.C. Wainwright initiates Agomab stock coverage with buy rating By Investing.com

H.C. Wainwright has initiated coverage on Agomab Therapeutics (NASDAQ:AGMB) with a buy rating and a price target of $35, citing significant upside potential from its current trading price of $10.98. The firm highlighted Agomab's promising pipeline of organ-restricted inhibitors f

Tone
Positive 82/100
Event
Analyst action
Published
22 Jun 2026 16:41
Source
Investing.com Nigeria
Stock Titan Direct company coverage

AGMB SEC Filings - AgomAb Therapeutics NV 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of AgomAb Therapeutics NV (AGMB) SEC filings, including annual reports, quarterly earnings, and material event disclosures. It highlights key recent filings such as LSP 7's 10.6% stake acquisition and the completion and filing details o

Tone
Positive 66/100
Event
Deals and strategy
Published
08 Jun 2026 23:09
Source
Stock Titan
Finviz Direct company coverage

AGMB - AgomAb Therapeutics NV ADR Stock Price and Quote

This article provides a comprehensive overview of AgomAb Therapeutics NV (AGMB) ADR stock, including its current price, key financial metrics, analyst ratings, and recent news. It highlights the company's focus on developing therapies for immunology and inflammatory diseases and

Tone
Positive 72/100
Event
Analyst action
Published
29 May 2026 19:40
Source
Finviz
Stock Titan Direct company coverage

All AGM agenda items approved at Agomab Therapeutics (NASDAQ: AGMB)

Agomab Therapeutics (NASDAQ: AGMB) announced that all agenda items presented at its Annual General Meeting on May 26, 2026, were approved. The company filed a Form 6-K to formally report these results, including the approval of financial statements, discharge of directors and aud

Tone
Neutral 50/100
Event
Earnings
Published
27 May 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

Shareholders back all Agomab proposals, reappoint 2 directors

Agomab Therapeutics NV announced that its shareholders approved all agenda items at the Annual General Meeting held on May 26, 2026. This included the approval of the 2025 financial statements, the discharge of directors and the auditor, and the reappointments of Ohad Hammer and

Tone
Positive 71/100
Event
Regulatory and legal
Published
27 May 2026 09:09
Source
Stock Titan
Moomoo Direct company coverage

Press Release: Agomab Announces Results of Annual General Meeting

Agomab Therapeutics NV announced the results of its Annual General Meeting of Shareholders, held on May 27, 2026. All proposed resolutions were approved by shareholders, including the re-election of Deloitte Bedrijfsrevisoren BV as statutory auditor. The company confirmed the com

Tone
Positive 70/100
Event
Earnings
Published
27 May 2026 09:09
Source
Moomoo
The Manila Times Direct company coverage

Agomab Announces Results of Annual General Meeting

Agomab Therapeutics NV announced the results of its Annual General Meeting (AGM) held on May 26, 2026. All agenda items were approved, including the financial statements for 2025, discharge of directors and auditor, and the reappointment of Mr. Ohad Hammer and Mr. Tim Knotnerus t

Tone
Neutral 50/100
Event
Earnings
Published
27 May 2026 09:09
Source
The Manila Times
Stock Titan Direct company coverage

Redmile (AGMB) holds 2.74M shares, a 5.6% stake in AgomAb

Redmile Group, LLC has reported a beneficial ownership of 2,735,926 Common Shares, representing a 5.6% stake in AgomAb Therapeutics NV (AGMB). This holding is composed of 2,579,676 Common Shares and 156,250 American Depositary Shares (ADS), with Redmile Biopharma Investments III,

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 May 2026 00:40
Source
Stock Titan
Stock Titan Direct company coverage

Cormorant reports 2.47M ADS stake in Agomab (NASDAQ: AGMB)

Cormorant Asset Management and Bihua Chen have filed a Schedule 13G, reporting a beneficial ownership of 2,465,348 American Depositary Shares (ADS) in Agomab Therapeutics NV (NASDAQ: AGMB), representing 5.01% of the common stock outstanding as of March 31, 2026. This filing indic

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 May 2026 00:40
Source
Stock Titan
Stock Titan Direct company coverage

Agomab to showcase IPF candidate AGMB-447 at ATS and investor events

Agomab Therapeutics announced its participation in several scientific and investor conferences in 2026. The company will present a poster on its idiopathic pulmonary fibrosis (IPF) candidate, AGMB-447, at the ATS International Conference, detailing preclinical and healthy subject

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 01:09
Source
Stock Titan